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Abstract
Objective
Multiple sclerosis (MS) develops as a result of environmental influences on the genetically
susceptible. Siblings of people with MS have an increased risk of both MS and demonstrat-
ing asymptomatic changes in keeping with MS. We set out to develop an MS risk score inte-
grating both genetic and environmental risk factors. We used this score to identify siblings
at extremes of MS risk and attempted to validate the score using brain MRI.
Methods
78 probands with MS, 121 of their unaffected siblings and 103 healthy controls were stud-
ied. Personal history was taken, and serological and genetic analysis using the illumina
immunochip was performed. Odds ratios for MS associated with each risk factor were
derived from existing literature, and the log values of the odds ratios from each of the risk
factors were combined in an additive model to provide an overall score. Scores were initially
calculated using log odds ratio from the HLA-DRB1*1501 allele only, secondly using data
from all MS-associated SNPs identified in the 2011 GWAS. Subjects with extreme risk
scores underwent validation studies. MRI was performed on selected individuals.
Results
There was a significant difference in the both risk scores between people with MS, their
unaffected siblings and healthy controls (p<0.0005). Unaffected siblings had a risk score
intermediate to people with MS and controls (p<0.0005). The best performing risk score
generated an AUC of 0.82 (95%CI 0.75–0.88).
Interpretations
The risk score demonstrates an AUC on the threshold for clinical utility. Our score enables
the identification of a high-risk sibling group to inform pre-symptomatic longitudinal studies.
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Introduction
No single factor appears to precipitate the development of multiple sclerosis (MS); a complex
interplay of risk factors provides overall risk [1]. Epidemiological data implicates both genetic
and environmental factors in disease development. Identifying and studying asymptomatic
individuals at high risk of MS provides a powerful opportunity to understand the MS causal
cascade. As the MS therapeutic armamentarium increases, the importance of early treatment
in influencing long-term outcomes has been realised. Early identification of MS risk provides
the opportunity to prevent fixed disability. Development of a predictive tool has the potential
to inform longitudinal studies, enriching trial populations with those at high risk of disease.
The majority of people with MS (PwMS) present with a clinically isolated syndrome (CIS), a
distinct first episode of demyelination [2]. Radiological abnormalities can be identified in the
absence of clinical symptoms, the “radiologically isolated syndrome” (RIS) [3]. Some of those
thought to have a RIS show subclinical cognitive impairment similar to the profile of early MS
[4], highlighting the prodromal nature of RIS. Approximately two-thirds of those with RIS
show new lesions on MRI and one-third develop clinical symptoms of demyelination during
mean follow-up times of up to five years [4].
There is a significant genetic contribution to MS. HLA-DRB11501 confers a relative risk of
MS among heterozygotes of around 3 (6.2 in homozygotes) [5]. A genome-wide association
study (GWAS) in 2011 [6] validated 23 non-MHC single nucleotide polymorphisms (SNPs)
contributing to MS risk, in addition to identifying a further 29 non-MHC SNPs and 4 MHC
alleles [6]. A second GWAS in 2013 [7] increased the number of MS-associated SNPs to 110.
Many of the SNPs identified are linked to immune system function.
MS is more common in females than in males, with an estimated relative risk (RR) of 2.62
[8]. A similar pattern is seen in both CIS and RIS [9]. Within regions of temperate climate, MS
incidence and prevalence increase with latitude [10]; population-based data demonstrates a
correlation betweenUV exposure and MS prevalence [11, 12]. High serum 25-hydroxyvitamin
D (25-OHvD) levels are associated with a lower risk of future MS [13].
Virtually all PwMS have evidence of prior infectionwith EBV compared to ~94% of age-
matched controls [14]. People with high IgG titres against the EBNA-1 EBV epitope have an
increased risk of developingMS compared to those with low titres [15, 16]. MS risk is increased
in those with a history of symptomatic primary EBV infection (infectiousmononucleosis) [17].
Smoking also increasesMS risk [18].
Siblings of PwMS have an increased risk of developingMS [19]. This risk is higher in those
more closely related to the MS proband; however concordance rates betweenmonozygotic
twins of<100% highlight environmental factors in disease aetiology. CSF oligoclonal IgG
bands are present in 19% siblings of PwMS compared to 4% healthy controls [20]. Asymptom-
atic MRI abnormalities suggestive of MS are seen in approximately 10% siblings of PwMS [21,
22] compared to 0.06% of the general population [23]. We suspect that those siblings with a
high number of MS risk factors may also have increased probability of CSF oligoclonal bands
and/or changes in keeping with MS on magnetic resonance imaging (MRI).
We set out to develop a risk score for the development of MS by integrating genetic and
environmental factors known to influenceMS risk using techniques described by De Jager et al
[24]. We then used this risk score to examine whether siblings occupy an “intermediate” score,
between people with MS and healthy controls. Should siblings occupy such an intermediate
score, then this would potentially indicate that the risk score provides some indication of over-
all MS risk. We also aimed to demonstrate that the inclusion of environmental factors into a
risk score is able to improve the area under the curve of a score when compared to scores using
genetic factors alone, or genetic factors with a single environmental component [24].
A Risk Score for MS
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Finally we studied whether it is possible to partition the intermediate sibling group into
those with a peripheral phenotype in keeping with MS versus healthy controls. We performed
a validation step by performing brain MR imaging on a subgroup of participants.
Materials and Methods
Sample size calculation
Existing data states that CSF OCBs are seen in 19% siblings of people with MS [20]; it would
seem logical that these siblings are at higher risk of MS than those without OCBs. Using this
data, 76 siblings are required to give a power of 0.8 and an alpha of 0.05 to detect a difference
in CSF OCBs (and hence highMS risk) between unaffected siblings and healthy controls. If
15% siblings have highMS risk, then 111 siblings are required to give power 0.8 and alpha 0.05.
Subjects
A total of 302 participants were enrolled: 78 probands with MS, 121 of their unaffected siblings
(including 6 monozygotic and 3 dizygotic twins), and 103 healthy controls (matched to the sib-
ling group with respect to gender and decade of age) who had no first or second-degree rela-
tives with MS. MS participants were recruited via MS clinics and publicity via local and
national MS charities. Siblings were recruited via the proband with MS. Healthy controls were
recruited via local recruitment and recruitment drives at various workplaces. This study had
ethical approval following review by the regional ethics committee (East London REC 1 (ref.
10/H0704/62). All participants gave informedwritten consent. Details of participants are given
in Table 1.
All participants were seen in person by a single investigator (RD). All patients and unaffected
siblings underwent neurological examination and a structured interview. Details regarding place
and month of birth, self-reported history of infectiousmononucleosis, smoking history, co-mor-
bid medical conditions, family history and medication (including vitamin supplementation)
were recorded. Blood draw and urine sample collectionwere performedon the same day.
Laboratory analysis
All serum samples were divided into aliquots and frozen at -80°c within 2 hours of blood draw.
Peripheral bloodmononuclear cells were separated and stored in liquid nitrogen on the day of
Table 1. Details of participants.
MS Unaffected siblings Healthy controls
Number 78 121 103
Age (mean; SD; range) 47.26 (11.74; 20–74) 47.24 (12.55; 18–75) 41.22 (11.33; 21–72)a
Gender (M:F; %F) 8:70 (89.7% F) 38:83 (68.6% F)b 33:70 (68.0% F)
Type of MS (n; %) • RRMS: 45 (69.2%)
• SPMS: 16 (20.5%)
• PPMS: 7 (9.0%)
Treatment (n; %) 37 (47.4%)c
EDSS (mean; range) 3.79 (0–8.5)
a: Healthy controls were significantly younger than people with MS (p<0.0005) and their siblings (p = 0.003), one way ANOVA.
b: Probands with MS were significantly more likely to be female than their unaffected sibling (p = 0.0005) and healthy controls (p = 0.0006), Fisher’s exact
test. There was no significant difference in the gender distribution of the groups between siblings and healthy controls.
c: 3 patients on Avonex, 2 on betaferon, 14 on Rebif, 14 on copaxone, 4 on Natalizumab and 2 on mitoxantrone (last dose >4 months ago for both).
doi:10.1371/journal.pone.0164992.t001
A Risk Score for MS
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blood draw. Analysis was performed in bulk on the day of thawing. Samples were not subject
to repeated freeze thaw cycles.
Anti-EBNA-1 IgG titres were measured using a commercially available ELISA (DiaSorin;
Salugia, Italy). Current smoking status was assessed using a commercially available cotinine
ELISA (Calbiotech; California,USA), a concentration of 3.08ng/ml was used to define current
smokers [25]. Serum25-OHvD levels were measured using liquid chromatography-tandem mass
spectrometry (Department of Clinical Biochemistry, Royal LondonHospital, Whitechapel).
Serum25-OHvD was deseasonalised to the day of sampling according to standard methods [26].
DNA was isolated from whole blood prior to genotyping using the Illumina immunochip
[27]. The immunochip provides SNP data for all SNPs associated with MS and a number of
other autoimmune diseases in GWAS; SNP data for the MS-associated alleles was isolated for
each individual and analysed.
Construction of a risk score
Odds ratios for MS associated with each risk factor were derived from the existing literature
(Table 2). Where available in the published literature, meta-analyses were used.Where meta-
analyses were not available, the odds ratios were taken from the largest available studies. Anti-
EBNA-1 IgG titres were assigned to quintiles derived using the combined healthy control and
sibling titres as the reference group [16]. As there are no published estimates for the odds ratio
of MS for each epoch of age, and there was no clear threshold age beyond whichMS risk
declines rapidly, the decision was taken not to include age as a risk factor in this MS risk score.
Deseasonalised serum 25-OHvD levels were assigned to quintiles according to the values
specifiedby Munger et al [13]. The only quintile that carried an odds ratio of MS significant
different to that of the lowest quintile was the highest quintile (Q5); for full details of all odds
ratios see Table 2. Participants who either described a smoking history and/or those with a
cotinine level greater than 3.08ng/ml were coded as “ever smoking”. 16 participants (3 MS, 5
siblings and 8 HC) had a positive cotinine ELISA despite reporting no current smoking. Only 1
Table 2. Summary of relative risks used in the calculation of an overall risk score. The risk associated with carriage of the HLA-DRB1*1501 haplotype
is given; for the risks associated with other HLA haplotypes and non-MHC SNPs see appendix 1.
Risk factor Relative risk used in risk score calculation Log value used in additive model
Gender (9) Female: 2.22 0.35
Month of birth (11) • April: 1.08
• May: 1.09
• October: 0.95
• November: 0.90
• 0.03
• 0.04
• -0.02
• -0.05
Previous infectious mononucleosis (17) 2.17 0.34
Quintile of IgG against EBNA-1 (16) • Undetectable titres: 0.33
• Q1 (lowest; reference): 1.0
• Q2: 2.6 (0.7–9.2)
• Q3: 3.2 (1.0–10.4)
• Q4: 5.1 (1.5–17.6)
• Q5: 9.4 (2.5–35.4)
• -0.48
• 0.00
• 0.00
• 0.51
• 0.71
• 0.97
Quintile of serum 25-OHvD (13) • Q1 (lowest; <63.2nmol/l): 1.0 (reference)
• Q2 (63.3–75.3nmol/l): 0.57 (0.3–1.07)
• Q3 (75.4–84.8nmol/l): 0.57 (0.3–1.07)
• Q4 (84.9–99.1nmol/l): 0.74 (0.4–1.36)
• Q5 (>99.2nmol/l): 0.38 (0.19–0.75)
• 0.00
• 0.00
• 0.00
• 0.00
• -0.42
Smoking status (18) Ever smoking: 1.52 0.18
HLA-DRB1*1501 haplotype (6) • Heterozygote: 3.1
• Homozygote: 6.2
• 0.49
• 0.79
doi:10.1371/journal.pone.0164992.t002
A Risk Score for MS
PLOS ONE | DOI:10.1371/journal.pone.0164992 November 1, 2016 4 / 13
participant described a current smoking habit but had a negative cotinine ELISA. All partici-
pants bar one reported a place of birth in the UK; therefore latitude of birth was not included
as a factor in the overall risk score.
The log values of the odds ratios from each of the risk factors were combined in an additive
model [24] to provide an overall score. The weighting given to each of the non-genetic risk fac-
tors and possession of the HLA-DRB11501 allele is given in Table 2. Details of the weighting
given to all genetic risk factors is provided in Table 3. Where a risk factor was not present, a
value of 0 was assigned for this risk factor. The total sum of all log odds ratio values was the
risk factor score for an individual.
Two models were derived, the initial model used the genetic data (i.e. log odds ratio) from
the HLA-DRB11501 allele only. Following this, a secondmodel was derived using data from
all MS-associated SNPs identified in the 2011 GWAS [6]. The decision was taken not to use all
SNPs identified in the 2013 GWAS [7], as the magnitude of the genetic score would far out-
weigh any environmental contribution to the score if all 110 genetic variants were included,
given the simple additive model. The risk score derived using all genetic information was used
to select participants for MRI.
Validation of the risk score
Magnetic resonance imaging. To determine if theMS risk score in siblings correlated with
the appearance of asymptomatic pathology, T2-weightedMR brain imaging was acquired to look
for MS-like white matter lesions and single voxel proton spectroscopy undertaken to look for
metabolic changes found in people withMS. 10 siblings with a high risk score and 10 siblings
with a low risk score underwent imaging studies. Scanningwas performedon a single Philips
Achieva 3 Tesla MRI system with the manufacturer’s product 32-channel head coil. All scans
were acquired within a threemonth period, during which there were no major hardware
upgrades or replacements. All subjects underwent scanning using the same protocol. PD/
T2-weighted images were acquired using a 2D turbo spin echo (2D-TSE) sequence (field of view
240 x 180mm, voxel size 1 x 1x 3mm over 50 slices; echo train length (ETL) = 10, repetition time
(TR) = 3500ms, echo time (TE) = 19/85ms, number of excitations (NEX) = 1; total scan time = 4
minutes). Image interpretation was performedby assessors blind to the risk status of participants.
Images were assessed by a radiologist (PS) and a neurologist trained in image interpretation (KS)
for the presence of T2 hyperintensities in keeping with demyelination using internationally
accepted criteria developed by MAGNIMS [28,29]. Single voxel proton spectroscopy
(TE = 32ms, TR = 2s, 20x10x10 mm voxel, PRESS localisationwithMOIST water suppression
and an identical water reference scan with noMOIST water suppression applied from the same
voxel) was undertaken in normal appearing brain white matter. LCModel was used to analyse
the spectra and to estimate the concentration of creatine and phosphocreatine, glycerophospho-
choline and phosphochocholine, and N-acetyl-aspartate and N-acetyl-aspartyl-glutamate, and
myo-inositol, using the water reference scan for quantification.
Statistical analysis. Statistical analysis was performed using PASW Statistics 18 (SPSS;
IBMUK). Normality was assessed using a Shapiro-Wilk test. Scores between three groups were
compared using a one-way ANOVA prior to post-hoc testing using a Bonferroni correction.
Receiver operating characteristic (ROC) curveswere generated using standard techniques.
Results
Risk score
The risk score was initially generated using the genetic information regarding HLA-DRB11501
only in addition to all of the environmental factors. The distribution of theMS risk score was
A Risk Score for MS
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Table 3. SNPs associated with MS available on the Illumina Immunochip.
SNP identified in GWAS Associated candidate gene Risk allele Odds Ratio associated with risk allele (6)
rs1315388 HLA-DRB1*1501 A 3.10
rs4648356 MMEL1 C 1.14
rs11810217 EV15 A 1.15
rs11581062 VCAM1 G 1.12
rs1335532 CD58 A 1.22
rs1323292 RGS1 A 1.12
rs7522462 C1orf106(KIF21B) G 1.11
rs12466022 no gene C 1.11
rs7595037 PLEK A 1.11
rs17174870 MERTK G 1.11
rs10201872 SP140 A 1.14
rs11129295 EOMES A 1.11
rs669607 no gene C 1.13
rs2028597 CBLB G 1.13
rs2293370 TMEM39A/CD80 G 1.13
rs9282641 CD86 G 1.21
rs2243123 IL12A G 1.08
rs228614 NFKB1 G 1.09
rs6897932 IL7R G 1.11
rs4613763 PTGER4 G 1.20
rs2546890 IL12B A 1.11
rs12212193 BACH2 G 1.09
rs802734 THEMIS A 1.10
rs11154801 MYB/AHI1 A 1.13
rs17066096 IL22RA2 G 1.14
rs13192841 no gene A 1.10
rs1738074 TAGAP G 1.13
rs354033 ZNF746 G 1.11
rs1520333 IL7 G 1.10
rs4410871 MYC G 1.11
rs2019960 PVT1 G 1.12
rs3118470 IL2RA G 1.12
rs1250550 ZMIZ1 A 1.10
rs7923837 HHEX G 1.10
rs650258 CD6 G 1.12
rs630923* CXCR5 C 1.12
rs1800693 TNFRSF1A G 1.12
rs10466829 CLEC1 A 1.09
rs12368653 CYP27B1 A 1.10
rs949143 ARL6IP4 G 1.08
rs4902647 ZFP36L1 G 1.11
rs2300603 BATF A 1.11
rs2119704 GALC/GPR65 C 1.22
rs2744148 SOX8 G 1.12
rs7200786 CLEC16A A 1.15
rs13333054 IRF8 A 1.11
rs9891119 STAT3 C 1.11
(Continued )
A Risk Score for MS
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Gaussian for all groups. Details regarding the risk scores are given in Table 4. There was a signifi-
cant difference in the risk score between people withMS and healthy controls (p<0.0005)
(Table 4 and Fig 1A). A ROC curve comparing people withMS with healthy controls generated
an area under the curve (AUC) of 0.77 (95% CI 0.70–0.84) (Table 4 and Fig 2A).
The contribution from all MS risk alleles was then used to derive the MS risk score
(Table 3). There was a significant difference in the risk score between people with MS and
healthy controls (p<0.0005) (Table 3 and Fig 1B). A ROC curve comparing people with MS
with healthy controls generated an improved AUC of 0.80 (95%CI 0.74–0.87) (Table 4 and Fig
2B).
People with MS had significantly higher deseasonalised serum 25-OHvD than unaffected
siblings and healthy controls; the patients with MS were taking vitamin D supplementation at
higher rates than either their siblings or healthy controls (data not shown). The risk scores
were therefore calculatedwithout the contribution from 25-OHvD. Under these conditions,
when the genetic contribution from HLA-DRB11501 only was included, the AUC was 0.80
(95% CI 0.73–0.87), and when all genetic information was included the AUC increased to 0.82
(95% CI 0.75–0.88) (Table 4 and Fig 2C and 2D).
Table 3. (Continued)
SNP identified in GWAS Associated candidate gene Risk allele Odds Ratio associated with risk allele (6)
rs180515 RPS6KB1 G 1.09
rs7238078 MALT1 A 1.12
rs1077667 TNFRSF14 G 1.16
rs8112449 TYK2/CDC37 G 1.08
rs874628 MPV17L2 A 1.11
rs2303759 DKKL1 C 1.11
rs2425752 CD40 A 1.11
rs2248359 CYP24A1 G 1.12
rs6062314 ZBTB46/TNFRSF6B A 1.16
rs2283792 MAPK1 C 1.10
rs140522* SCO2 A 1.10
Odds ratios taken from (6).
doi:10.1371/journal.pone.0164992.t003
Table 4. Risk scores and area under a ROC curve for each group and risk score respectively.
MS
(n = 73)
Siblings
(n = 107)
Healthy controls
(n = 99)
Area under curve
(95% CI)
Risk score including genetic contribution from HLA-DRB15*1501 only
(mean; SD)
2.82
(1.18)a
1.98 (1.38)b 1.53 (1.34) 0.77 (0.70–0.84)
Risk score including genetic contribution from all MS risk alleles (mean;
SD)
9.71
(1.38)c
8.83 (1.47) 8.00 (1.49) 0.80 (0.74–0.87)
Risk score including genetic contribution from HLA-DRB1*1501 only;
excluding serum 25-OHvD level (mean; SD)
3.13
(1.12)
2.16 (1.33) 1.74 (1.32) 0.80 (0.73–0.87)
Risk score including genetic contribution from all MS risk alleles; excluding
serum 25-OHvD level (mean; SD)
10.02
(1.38)
9.00 (1.44) 8.20 (1.48) 0.82 (0.75–0.88)
a: p<0.0005 for difference between MS and siblings and MS and HC
b: p = 0.042 for difference between siblings and HC
c: p<0.0005 for difference between MS and siblings, MS and HC and siblings and HC.
doi:10.1371/journal.pone.0164992.t004
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Risk score: siblings
The sibling group appeared to occupy an intermediate risk score. There was a significant differ-
ence in the risk scores using HLA type between the three groups (p<0.0005; one-way
ANOVA) (Table 4 and Fig 3). People with MS had a significantly higherMS risk score than
their unaffected siblings (p<0.0005), and unaffected siblings had higher scores than healthy
controls (p = 0.042) (Table 4 and Fig 3). The same was true when all MS risk alleles were used
to derive the risk score, with post-hoc testing demonstrated significant differences between all
pairwise combinations (p<0.0005 for all comparisons).
Using the risk score to identify high risk siblings. The risk score was partitioned into 7
categories based on the risk score distribution within that group (+/- 0.25, 0.75 and 1.25 SD
from the mean). Comparisons were carried out between the sibling group and the healthy con-
trol group. As would be expected, when the lowest septiles of the sibling group were selected,
the risk score was significantly different from that of healthy controls. When septiles 1–5 of the
sibling group were selected then the groups did not significantly differ (sibs mean score 1.33 vs
HC 1.51). When septiles 1–6 of the sibling group were selected, again the groups did not signif-
icantly differ (sibs mean score 1.68 vs HC 1.51). When the full sibling group was included the
groups significantly differed (see above), indicating that it was only the highest septile of the
sibling group that gave rise to the overall difference in mean values.
Using these data to inform future longitudinal studies. Given that the group consisting
of septiles 1–6 of the sibling group have a risk score distribution not significantly different to
that of healthy controls, it would seem reasonable to use siblings with risk scores in the highest
septile to inform power calculations for enriching pre-symptomatic trials. From our data this
would equate to 10.3% siblings.
MRI. One participant in the group with highMS risk score developed clinically definite
MS prior to the imaging stage; this participant did not have exploratory imaging. There was no
significant difference between the high and low risk imaging groups in terms of number or
location of lesions. One participant in each group had changes that could be described as
Fig 1. Combined scatter and box-and-whisker plot demonstrating the MS risk score distribution between people
with MS and healthy controls. The box indicates the interquartile range, bisected by the median, and the whiskers the
range. (a) Where HLA-DRB1*1501 is the only genetic information used to derive the risk score. (b) Where full genetic
information is used to derive the MS risk score.
doi:10.1371/journal.pone.0164992.g001
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“possible demyelination” according to accepted criteria [28,29]. Single voxel spectroscopy did
not demonstrate any difference in the concentration of either NAA, NAA-G or myo-inositol in
normal appearing white matter between siblings with high and low risk scores.
Discussion
Developing a tool to stratifyMS risk may enable preventative trials to be sufficiently powered,
something that is currently not possible. The MS risk score reported here demonstrates perfor-
mance characteristics at the threshold accepted for clinical utility. ROC analysis demonstrated
an area under the curve score of 0.82, i.e. just below 0.85 [30], the figure generally accepted as
being clinically useful. Our study demonstrates that it is possible to create a multivariate MS
risk score with real potential to inform the clinical discussionwith relatives of people with MS
beyond currently available tools.
Our finding that 90% of siblings lie in septiles 1–6 with overall risk score distribution not
significantly different frommatched healthy controls gives an indication as to how these data
can be used to inform longitudinal clinical trials. Enriching such trials with siblings at the high-
est risk of MS at baseline would potentially reduce the number of participants that require fol-
low up. By screening participants using an MS risk score at baseline, only the 10% of siblings in
the highest risk groups need by subject to intensive monitoring. Refining intensive monitoring
to this 10% has clearly significant implication for feasibility of longitudinal studies.
Fig 2. A receiver operating characteristic (ROC) curve generated by the MS risk score when the score of people with
MS is compared to that of healthy controls. (a) Including HLA-DRB1*1501 only. (b) Including full genetic information. (c)
Including genetic information from HLA-DRB1*1501 only, and excluding serum 25-hydroxyvitamin D levels. (d) Including full
genetic information, and excluding serum 25-hydroxyvitamin D levels.
doi:10.1371/journal.pone.0164992.g002
A Risk Score for MS
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An alternative means of identifying people at high risk of developingMS could be to screen
large numbers of potential participants using MRI to identify those with radiologically isolated
syndrome, RIS. However, MRI screening of large numbers of people is both expensive and
time consuming for both participants and investigators, whereas many of the factors used in
our risk score can be determined from clinical history, with the rest amenable to batch analysis
at relatively low cost. In addition, the disease process may well be already established in those
with RIS [1]. Our risk score therefore provides a feasible method to detect those with truly
asymptomatic disease in large population-based studies.
Whilst the validation step using MRI markers of MS risk did not demonstrate any signifi-
cant differences between the siblings with high risk score and those with low risk score, longitu-
dinal studies with years of follow up to determine bothMRI and clinical conversion rates are
the only accurate way to determine the accuracy of any predictive score. Our study provides
evidence that it is feasible to develop such a score and hints that it may be worthy of further
study.
The risk score can also contribute to our understanding of the causal cascade that eventually
results in MS onset. The AUC improves as increasing numbers of SNPs MS are included; how-
ever it seems unlikely that expanding the genetic contribution will eventually result in a “per-
fect” score. It seems likely that consideration of gene-environment interactions will result in
meaningful improvement in such a score.
Studies to examine gene-environment interactions would have to be multinational collabo-
rations over many decades, thereby posing significant problems of feasibility. An illustrative
model implied a marked potential effect of such interactions on the OR calculated by GWAS,
Fig 3. Combined scatter and box-and-whisker plot demonstrating the MS risk score distribution between people
with MS and healthy controls. The box indicates the interquartile range, bisected by the median, and the whiskers the
range. Full genetic information is used to derive the MS risk score.
doi:10.1371/journal.pone.0164992.g003
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with an increase in the OR of up to 16.8 from a GWAS estimated OR of 1.3 [31]. Other poten-
tially important contributors to MS risk are rare alleles associated with large effect sizes. These
low frequency variants are not present on current SNP genotyping arrays. Individual disease
risk may be influenced by rare or private (confined to one individual/family)mutations.
One environmental factor that has been shown to be associated with later MS risk is child-
hood obesity [32]; childhoodweight also interacts with a history of infectiousmononucleosis
[33]. However, we did not have access to the medical records of the majority of participants
and so had no accurate measure of BMI in childhood. There is good evidence that on an indi-
vidual basis there is poor recollection of childhoodweight [34], and that recollectionmay be
affected by a number of factors including cognitive ability, which could differ significantly
between groups and not be possible to control for in this study. We therefore decided not to
include this in our risk score; however it is likely that the risk score could be improved if an
accurate measure of childhoodweight was available for future participants.
Whilst the decision not to include age as an MS risk factor was valid in this pilot study, age
is an important factor in any longitudinal study. MS risk declines with increasing age after a
threshold age; people aged>60 years are unlikely to develop clinically definiteMS within their
lifetime and so have low risk due to age alone. We would suggest that if this risk score were to
be used to enrich prevention trials, such trials should exclusively enrol younger participants
under a threshold age where the risk of developingMS remains relatively high. In this explor-
atory study, we suspect that the relatively high mean age of siblings reduced the risk of asymp-
tomatic demyelinating lesions in this group, thus contributing to the non-significantMRI data.
Whilst major known genetic and environmental risk factors have been included in the
model describedhere, it appears evident significant further risk factors have yet to be identified.
It also raises questions about risk factors for developing an MS-like pathological process and
risk factors for this manifesting as neurological deficits, and these need not be identical.
In the sub-groups who underwentMRI, no differences in T2-weighted lesion loads or brain
white matter metabolite concentrations was observed.With due caution given the relatively
small number of participants who were imaged, and it may be that imaging the entire cohort is
needed to fully assess the distribution of risk, this observation suggests that even in those at rel-
atively high risk of developingMS, further initiating event(s) or acquired risk factor(s) are
required before a fully fledged neuroinflammatory process is initiated that is detectable by
MRI.
The current model needs to be validated in a larger cohort, but it is also likely that further
factors–and their interaction(s)–will have to be discovered to create a more definitive risk
score. Clearly longitudinal follow-up of selected groups, stratified according to estimated risk is
the gold standard to validate any risk score, however such studies are require proof-of-concept
preliminary studies, such as this one, to enable power calculations to be performed.However,
as it stands our current model appears to be powerful enough to test hypotheses regarding MS
development and has potential to enable directed preventative studies.
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